Continuous Oral Contraceptive Study

IRB #2907

This is a four month opportunity using an FDA approved oral contraceptive to study the use of doxycyline in preventing breakthrough bleeding. Eligible participants will receive contraception and study drug at no cost. Participants will be compensated for time and travel.

Vaginal Ring Study

IRB #3019

The Women's Health Research Unit is currently recruiting for a new contraceptive ring. As opposed to the ring on the market, this can be used for up to one year. Eligible participants will receive contraception at no cost for one year, and compensation at the completion of the study.

View clip on this study from KOIN TV: WMV Format (4.4 MB) -- or -- MP4 Format (6.5 MB)

Pelvic Floor Nerve Injury Following Childbirth

IRB #3196

This study looks at features of a woman’s anatomy, musculature and nerves before and after delivering a first child, as well as how those are associated with the lacerations (tears or cuts) and the symptoms of incontinence that happen as a result of childbirth.

Vaginal Health Study

IRB #2017

Qualifying participants (between ages 18-35) will be randomized to either an oral contraceptive pill (Desogen®) or the vaginal ring (NuvaRing®) to see whether the route by which women receive hormonal contraception causes different changes to occur in the lining of the vagina. This is a 3-visit, 6-month study at the end of which compensation will be provided to participants if all visits are completed. All tests and procedures will be provided to the participant at no cost.

The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle

IRB #3854

We are evaluating the effect Celebrex may have on the length of a woman’s menstrual cycle.  Qualifying participants in this 3-month study may receive blood tests, compensation, and study drug.  We are looking for healthy women aged 18-35 with regular menstrual cycles and not currently using hormonal contraception.

Low Dose, Intrauterine Contraception

IRB #3829

We are evaluating the safety and efficacy of 2 new low dose Levonorgestrel Intrauterine Device systems (12 ug/24 h or 16 ug/24h).  Qualifying participants in this 3 year research study may receive study related exams, blood tests, and study drug at no cost.  Subjects have a 50% chance of being randomized into one of the treatment groups. Participants will be compensated for time and travel.

Coming soon!

Study opportunities in the areas of hot flashes, sterilization, osteoporosis and a new contraceptive pill with folate. Please call our confidential recruitment line at 503 494-3666 to learn more about these studies or to get on a wait list as a potential participant.